Talis Biomedical Corporat... (TLIS)
Talis Biomedical Statistics
Share Statistics
Talis Biomedical has 1.82M shares outstanding. The number of shares has increased by 0.04% in one year.
| Shares Outstanding | 1.82M |
| Shares Change (YoY) | 0.04% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.83% |
| Shares Floating | 1.16M |
| Failed to Deliver (FTD) Shares | 2 |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 17.96K, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 17.96K |
| Short % of Shares Out | 0.99% |
| Short % of Float | 2.35% |
| Short Ratio (days to cover) | 0.59 |
Valuation Ratios
The PE ratio is -0.22 and the forward PE ratio is -0.07. Talis Biomedical's PEG ratio is 0.
| PE Ratio | -0.22 |
| Forward PE | -0.07 |
| PS Ratio | 32.87 |
| Forward PS | 0.2 |
| PB Ratio | 0.2 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Talis Biomedical.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.86, with a Debt / Equity ratio of 0.28.
| Current Ratio | 8.86 |
| Quick Ratio | 8.86 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | -0.3 |
| Debt / FCF | -0.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $4.16K |
| Profits Per Employee | $-626.33K |
| Employee Count | 99 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -79.36% in the last 52 weeks. The beta is 1.47, so Talis Biomedical's price volatility has been higher than the market average.
| Beta | 1.47 |
| 52-Week Price Change | -79.36% |
| 50-Day Moving Average | 1.67 |
| 200-Day Moving Average | 3.2 |
| Relative Strength Index (RSI) | 61.64 |
| Average Volume (20 Days) | 1.41K |
Income Statement
In the last 12 months, Talis Biomedical had revenue of 412K and earned -62.01M in profits. Earnings per share was -34.12.
| Revenue | 412K |
| Gross Profit | 371K |
| Operating Income | -66.81M |
| Net Income | -62.01M |
| EBITDA | -66.05M |
| EBIT | -66.81M |
| Earnings Per Share (EPS) | -34.12 |
Balance Sheet
The company has 76.73M in cash and 19.67M in debt, giving a net cash position of 57.06M.
| Cash & Cash Equivalents | 76.73M |
| Total Debt | 19.67M |
| Net Cash | 57.06M |
| Retained Earnings | -539.96M |
| Total Assets | 72.7M |
| Working Capital | 55.41M |
Cash Flow
In the last 12 months, operating cash flow was -53.24M and capital expenditures -486K, giving a free cash flow of -53.73M.
| Operating Cash Flow | -53.24M |
| Capital Expenditures | -486K |
| Free Cash Flow | -53.73M |
| FCF Per Share | -29.56 |
Margins
Gross margin is 90.05%, with operating and profit margins of -16217.23% and -15050.24%.
| Gross Margin | 90.05% |
| Operating Margin | -16217.23% |
| Pretax Margin | -15050.24% |
| Profit Margin | -15050.24% |
| EBITDA Margin | -16030.34% |
| EBIT Margin | -16217.23% |
| FCF Margin | -13040.29% |
Dividends & Yields
TLIS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for TLIS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 6, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Jul 6, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -12.33 |
| Piotroski F-Score | 1 |